PATENT CLAIM ANALYSIS

Application Number: 16352167
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["514", "648000"]

Abstract:
Disclosed are methods and topical formulations for treating and/or preventing cell proliferative diseases and disorders including breast cancer and ductal carcinoma is situ (DCIS) using local transdermal therapy (LTT). The disclosed methods typically include administering topically to the breast or breasts of the patient a topical formulation comprising an effective dose of the tamoxifen metabolite, N-desmethyl-4-hydroxytamoxifen (i.e., endoxifen or ENX) for treating breast cancer. The topical formulation may be described as a transdermal formulation and the topical formulation may comprise, consist essentially of, or consist of endoxifen as an active ingredient.

Claim (Index 26):
The topical formulation of  claim 25 , wherein the fatty acid is oleic acid.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 99.0
- Lexical Diversity: 1.625
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15842523', '14382356', '15147715', '12914830', '15807185']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7766634277667038
- 35 USC 102 Novelty (BERT): 0.6507601960502848
- Combined Prediction Score: 0.764073104595062
- Mean Citation Score: 362.469836
- Max Citation Score: 848.6124
- Similarity Product: 566.9508119994879

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test